摘要
癌症是一种多基因改变的进化性疾病,由于染色体不稳定性和/或非整倍体而累积,并且它有时也获得了耐药表型。全基因组测序和突变分析有助于了解人们对疾病易感性及其治疗无反应性的差异。因此,分子靶向治疗成立。其中,合成致死性的概念备受瞩目,因为它是一种实用的方法,旨在利用癌细胞特异性突变特异性杀死癌细胞而不影响正常细胞,从而提高抗癌药治疗指数。因此,这种方法有助于发现用于精密医学发展的新型治疗分子。纳米技术有助于将这些分子以有效浓度输送到靶位点,从而减少药物,剂量和剂量频率药物的脱靶效应。研究人员试图通过将其纳入纳米颗粒来实现针对靶向癌细胞杀伤的合成致死性合作伙伴的siRNA,并通过预防肿瘤进展显示了其功效。本综述总结了合成致死性和合成致死基因相互作用的简要介绍,重点介绍了其应用纳米技术开发个性化医疗的治疗性抗癌潜力。
关键词: 合成致死性,精确纳米药物,靶向药物递送,耐药表型,纳米技术,功效。
图形摘要
Current Cancer Drug Targets
Title:Synthetic Lethality: From Research to Precision Cancer Nanomedicine
Volume: 18 Issue: 4
关键词: 合成致死性,精确纳米药物,靶向药物递送,耐药表型,纳米技术,功效。
摘要: Cancer is an evolutionary disease with multiple genetic alterations, accumulated due to chromosomal instability and/or aneuploidy and it sometimes acquires drug-resistant phenotype also. Whole genome sequencing and mutational analysis helped in understanding the differences among persons for predisposition of a disease and its treatment non-responsiveness. Thus, molecular targeted therapies came into existence. Among them, the concept of synthetic lethality have enthralled great attention as it is a pragmatic approach towards exploiting cancer cell specific mutations to specifically kill cancer cells without affecting normal cells and thus enhancing anti-cancer drug therapeutic index. Thus, this approach helped in discovering new therapeutic molecules for development of precision medicine. Nanotechnology helped in delivering these molecules to the target site in an effective concentration thus reducing off target effects of drugs, dose and dosage frequency drugs. Researchers have tried to deliver siRNA targeting synthetic lethal partner for target cancer cell killing by incorporating it in nanoparticles and it has shown efficacy by preventing tumor progression. This review summarizes the brief introduction of synthetic lethality, and synthetic lethal gene interactions, with a major focus on its therapeutic anticancer potential with the application of nanotechnology for development of personalized medicine.
Export Options
About this article
Cite this article as:
Synthetic Lethality: From Research to Precision Cancer Nanomedicine, Current Cancer Drug Targets 2018; 18 (4) . https://dx.doi.org/10.2174/1568009617666170630141931
DOI https://dx.doi.org/10.2174/1568009617666170630141931 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Onychine and its Analogs: Synthesis and Biological Activity
Current Organic Synthesis Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Editorial [Hot Topic: New Antidepressant Drugs: Beyond Monoaminergic Mechanisms (Executive Editors: Cecilio Alamo and Francisco Lopez-Munoz)]
Current Pharmaceutical Design Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Synthetic and Medicinal Perspective of Fused-Thiazoles as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry CD248: Reviewing its Role in Health and Disease
Current Drug Targets Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors
Current Pharmaceutical Design Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume 2
Current Nutrition & Food Science New Insights in Testing and Imaging Techniques for Solid Tumor Response Evaluation
Neuroscience and Biomedical Engineering (Discontinued) Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Pharmacogenomics of Human Multidrug Resistance Associated Proteins
Current Pharmacogenomics and Personalized Medicine Classification Methods in Chemometrics
Current Analytical Chemistry A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Effects of the Novel Non-Peptidyl Low Molecular Weight Radical Scavenger IAC in Different Models of Inflammation: A New Perspective in Anti-Inflammatory Therapy
Current Medicinal Chemistry Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry